GoKawiilWeekly-equivalent semaglutide dosing extends lifespan in aged female mice, Berkeley study finds
Researchers at UC Berkeley gave 20-month-old female mice daily low-dose subcutaneous semaglutide, the active ingredient in drugs like Ozempic and Wegovy, and compared them with saline-treated and calorie-restricted counterparts. Over months of treatment, the semaglutide group showed slowed markers of aging and, in a full lifespan cohort of about 80 mice, longer survival than untreated controls.
GoKawiil's interpretation of the reporting above, not reported fact.
Semaglutide is already used by millions for weight loss and diabetes, so evidence that it can also blunt biological aging in animals raises the possibility of repurposing GLP-1 drugs as longevity treatments, not just metabolic ones. It also suggests the drug's benefits may extend beyond weight reduction alone, since researchers compared it against calorie restriction to separate the two effects.
- Aged female mice given daily semaglutide lived longer than saline-treated controls in an ~80-mouse lifespan study.
- Separate cohorts underwent physiological, molecular and cellular analysis after 3-5 months of treatment to identify mechanisms.
- The study included calorie-restricted mice as a comparison group to test whether reduced food intake alone explains the effects.
Source: nature.com — Feng, 2026-09-02
Published there as: “Late-life semaglutide treatment slows ageing and extends lifespan in female mice”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.